ArticleMolecular medicine reports2025
Curcumin exerts therapeutic effects on colorectal cancer by inducing pyroptosis through caspase‑1 activation.
Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond apoptosis: harnessing natural products to target alternative regulated cell death for overcoming multidrug resistance in cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a substantial global health challenge, with current treatments often leading to relapse and metastasis. Curcumin, a natural compound derived from turmeric, has shown promise in cancer therapy; however, its mechanisms in CRC are not fully understood. The present study aimed to investigate the role of curcumin in inducing pyroptosis, a form of inflammatory cell death, through caspase‑1 activation in CRC cells. Human CRC cell lines (HCT‑116 and SW480) and normal colon epithelial cells (FHC) were treated with curcumin at varying concentrations. Cell viability, migration and invasion were assessed using Cell Counting Kit‑8, wound healing and Transwell assays, respectively. Pyroptosis was evaluated through lactate dehydrogenase (LDH) release, TUNEL staining and western blot analysis of pyroptosis‑related proteins (caspase‑1, gasdermin D, nucleotide‑binding oligomerization domain‑like receptor protein 3, IL‑1β and IL‑18). The role of caspase‑1 was further examined using the inhibitor VX‑765. Curcumin significantly reduced CRC cell viability, migration and invasion in a dose‑dependent manner. In addition, it induced pyroptosis, as evidenced by cell membrane swelling, increased LDH release and upregulation of pyroptosis‑related proteins. Inhibition of caspase‑1 with VX‑765 attenuated these effects, confirming the role of caspase‑1 in curcumin‑induced pyroptosis. In conclusion, curcumin may exert anti‑CRC effects by inducing caspase‑1‑mediated pyroptosis, highlighting its potential as a therapeutic agent. These findings suggest that curcumin could be integrated into current CRC treatment strategies, particularly in targeting pyroptosis to enhance tumor suppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.